Skip to content

Homepage

Author: Vivos Therapeutics, Inc

Posted Date:

June 30, 2026

Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

Vivos Therapeutics, Inc

June 30, 2026
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity

Vivos Therapeutics, Inc

June 22, 2026
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics, Inc

June 11, 2026
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics, Inc

June 10, 2026
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics, Inc

June 8, 2026
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics, Inc

June 5, 2026
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

Vivos Therapeutics, Inc

April 7, 2026
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved ‘In-Network’ Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

Vivos Therapeutics, Inc

March 26, 2026
Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy

Vivos Therapeutics, Inc

March 17, 2026
Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies

Vivos Therapeutics, Inc

February 7, 2026